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The origin of tumor-infiltrating Tregs, critical mediators of tumor immunosuppression, is unclear. Here, we show 
that tumor-infiltrating naive CD4+ T cells and Tregs in human breast cancer have overlapping TCR repertoires, while 
hardly overlap with circulating Tregs, suggesting that intratumoral Tregs mainly develop from naive T cells in situ 
rather than from recruited Tregs. Furthermore, the abundance of naive CD4+ T cells and Tregs is closely correlated, 
both indicating poor prognosis for breast cancer patients. Naive CD4+ T cells adhere to tumor slices in proportion to 
the abundance of CCL18-producing macrophages. Moreover, adoptively transferred human naive CD4+ T cells infil-
trate human breast cancer orthotopic xenografts in a CCL18-dependent manner. In human breast cancer xenografts 
in humanized mice, blocking the recruitment of naive CD4+ T cells into tumor by knocking down the expression of 
PITPNM3, a CCL18 receptor, significantly reduces intratumoral Tregs and inhibits tumor progression. These find-
ings suggest that breast tumor-infiltrating Tregs arise from chemotaxis of circulating naive CD4+ T cells that differen-
tiate into Tregs in situ. Inhibiting naive CD4+ T cell recruitment into tumors by interfering with PITPNM3 recogni-
tion of CCL18 may be an attractive strategy for anticancer immunotherapy.
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Introduction
Regulatory T cells (Tregs), a subset of immunosup-
pressive Foxp3+CD25+CD4+ T cells that play an import-
ant role in maintaining self-tolerance, are enriched in 
many cancers. Tregs suppress the anti-tumor function 
of effector T cells and natural killer cells by secreting 
soluble immunosuppressive factors, such as TGF-β, and 
expressing inhibitory receptors such as CTLA4 [1, 2]. 
A high proportion of Tregs in tumor-infiltrating (TI) T 
cells in cancer specimens from many types of human 
cancer is associated with poor prognosis [3, 4]. Elim-
ination of Tregs with an anti-CD25-coupled toxin has 
shown promise in early-phase clinical trials [5, 6]. Ani-
mal studies also suggest that Tregs play a pivotal role in 
tumor immune escape [2]. The clinical benefit of check-
point blockade with anti-CTLA4 has also been partially 
attributed to depletion of TI Tregs [7]. Together, these 
results suggest that Tregs are promising targets for an-
ti-tumor immunotherapy. However, systemic suppression 
of Tregs can induce severe autoimmune complications [8]. 
Therefore, strategies to selectively deplete TI Tregs with-
out interfering with systemic immune homeostasis would 
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be ideal for tumor immunotherapy. However, developing 
such strategies requires an understanding of the source of 
TI Tregs and what distinguishes TI Tregs from circulat-
ing Tregs and Tregs at normal tissue sites. Surprisingly, 
little is known about how TI Tregs arise [1, 3, 9].
The goal of this study is to understand how human 
breast TI Tregs are generated. The prevailing idea is that 
TI Tregs are recruited from preexisting circulating Tregs 
by chemokines or chemokine ligands expressed by tumor 
cells, stroma or tumor-associated macrophages (TAMs). 
Several chemokine-chemokine receptor pairs have been 
proposed to be responsible for recruiting Tregs to tumors 
including chemokine receptors CCR4, CCR10, CCR8 
or CXCR3 expressed on infiltrating Tregs, responding 
to CCL22, CCL28, CCL1 or CXCL9-11 in the tumor 
microenvironment, respectively [10-12]. An alternative 
possibility is that naive or conventional T cells might be 
recruited to the tumor and differentiate to Tregs in situ 
within the immunosuppressive tumor environment [1, 9, 
13]. Here we show that the TAM-produced chemokine 
CCL18 recruits circulating naive CD4+ T cells to breast 
tumors by binding their PITPNM3 receptor. Further-
more, TCR repertoire analysis suggests that Tregs in hu-
man breast cancer are mainly derived from naive CD4+ T 
cells. In human breast cancer xenograft models, blocking 
CCL18-mediated recruitment of naive T cells into tumors 
reduces TI Tregs and inhibits tumor progression.
Results
The TCR clonotypes of breast TI Tregs most closely re-
semble those of naive CD4+ T cells in the tumor and pe-
ripheral blood
To begin to evaluate whether Tregs in breast tumors 
are mainly recruited from peripheral blood (PB) or con-
verted in situ from other CD4+ lymphocyte subtypes, we 
isolated Tregs (CD4+CD25+CD127−/low), naive CD4+ T 
cells (CD4+CD45RA+CD25−) and memory CD4+ T cells 
(CD4+CD45RO+CD25−) from breast cancers (tumor in-
filtrating, TI), PB and ipsilateral draining lymph nodes 
(LN) of 5 breast cancer patients and used next-generation 
sequencing to compare their TCR-β/α repertoires (Fig-
ure 1A). The purity of the isolated cell populations was 
> 90% (Supplementary information, Figure S1). 5′ rapid 
amplification of cDNA ends (RACE) PCR was used to 
amplify the full-length variable regions of all TCR-β/α 
genes in each sample. The mapped reads showed grossly 
similar TCR-β/α gene usage in TI, PB and LN T cells 
(Figure 1B and Supplementary information, Figure S2), 
consistent with a recent report on TI T cell repertoire 
based on data in the Cancer Genome Atlas [14].
To look for more subtle differences, we pooled the 
TCR sequencing data for each of the nine sources of 
CD4+ T cell subsets (Treg, naive and memory CD4+ T 
cells from tumor, LN and blood) from all five patients 
[15] and used unsupervised clustering to compare their 
TCR-α and TCR-β usage [16]. For both subunits, TCR 
gene usage in TI Tregs was most similar to that of TI and 
PB naive CD4+ T cells, whereas gene usage of TI memo-
ry CD4+ T cells clustered with PB and LN memory CD4+ 
T cells, and LN naive CD4+ T cells (Figure 1C). Next we 
studied what proportion of the individual TCR sequences 
of TI Tregs was identical to those from the other groups 
[17]. The TCR sequences of both TCR-β and -α from TI 
Tregs overlapped most with the sequences of TI naive 
CD4+ T cells and then with PB naive CD4+ T cells (Figure 
1D). 
The TCR sequences of TI Tregs and the same subsets 
of PB CD4+ T cells were compared in a larger group of 
23 breast cancer patients by studying the TCR sequences 
of a single VβJβ gene rearrangement (TRBV12-4/TRBJ1-
2). Within this set of gene rearrangements, 12.9% ± 3.2% 
of the TI Treg sequences overlapped with 4.9% ± 1.1% 
of the CD4+ naive T cell sequences, whereas a signifi-
cantly much smaller proportion of clonotypic sequences 
(< 2%) was identical between TI Tregs and PB Tregs or 
CD4+ memory T cells (Figure 1E). Thus the TCR clono-
types of TI Tregs are most similar to those of TI and PB 
naive CD4+ T cells, suggesting that TI Tregs might de-
velop from naive CD4+ T cells recruited from the blood.
The abundance of naive CD4+ T cells in breast cancer 
samples is associated with increased TI Tregs and poor 
prognosis
We next evaluated by immunohistochemistry (IHC) 
whether we could detect naive T cells within clinical 
breast cancer tissues. CD3+CD45RA+ naive T cells were 
detected in 74% (462 of 626 cases) of clinical breast 
cancer tissues, predominantly in the perivascular space 
(Figure 2A). The number of naive CD4+ T cells positive-
ly correlated with the numbers of Tregs in tumors (P < 
0.0001; Figure 2B). In contrast, the number of memory 
CD4+ T cells (CD4+CD45RO+Foxp3−) in tumors neg-
atively correlated with the number of Tregs and naive 
CD4+ T cells in the slides (Supplementary information, 
Figure S3A). We also used immunofluorescence micros-
copy to analyze serial breast tumor sections stained for 
CD3 and CD4, and either CD45RA (naive CD4+ T cells) 
or Foxp3 (Tregs). Naive CD4+ T cells were more prom-
inent in the perivascular space, whereas the majority of 
Tregs were far from blood vessels and localized close to 
the tumor parenchyma (Figure 2C, Supplementary infor-
mation, Figure S3B and S3C). These data are consistent 
with the possibility that naive CD4+ T cells entering from 
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the blood differentiate into Tregs after they migrate to-
ward the tumor. 
We next evaluated whether a high number of TI na-
ive CD4+ T cells has prognostic significance. We used 
X-Tile software to separate the 626 patient samples into 
one group (113 patients) with a high number of TI naive 
CD4+ T cells (> 3.8 cells per field) and another group (513) 
with a lower number. The patients with more TI CD4+ 
naive T cells had significantly reduced disease-free sur-
vival (P < 0.004; Figure 2D and 2E). By contrast, a paral-
lel analysis showed that naive CD8+ T cell abundance did 
not correlate with disease-free survival (Supplementary 
information, Figure S3D and S3E). A significantly higher 
TI naive CD4+ T cell count was associated with other 
indicators of poor prognosis — triple-negative breast 
cancer subtype, lymphovascular invasion, LN metasta-
sis and distant metastases (Supplementary information, 
Table S1). Multivariate analysis demonstrated that the 
abundance of TI naive CD4+ T cells was an independent 
prognostic factor (Supplementary information, Table 
S2). In addition, a higher number of TI memory CD4+ 
T cells was significantly associated with good prognosis 
(Supplementary information, Figure S3F), whereas Treg 
accumulation was associated with poor prognosis (Sup-
plementary information, Figure S3G).
To confirm the clinical significance of TI naive CD4+ 
T cells, we stained tumor sections for another naive T 
cell marker, CD62L [18] (Supplementary information, 
Figure S4A). CD3+CD4+CD62L+ cell counts significantly 
correlated with CD3+CD4+CD45RA+ cell counts (Sup-
plementary information, Figure S4B) and were also sig-
nificantly associated with poor prognosis (Supplementary 
information, Figure S4C). To confirm the association of 
naive CD4+ T cells with poor prognosis in independent 
large cohorts, we analyzed the correlation of CD4+ naive 
T cell-associated gene expression with clinical progno-
sis in the Curtis and Hatzis data sets, two of the largest 
breast cancer case lists in the online database Oncomine. 
Because data on CD45RA expression and some clinical 
parameters are not available in Oncomine, we analyzed 
the correlation between the annotated clinical variables 
with expression of CD4 and CD62L. Patients in each 
data set were divided into two groups with or without 
high expression of both CD4 and CD62L using X-Tile. 
High expression of both genes was significantly associ-
ated with increased LN metastasis in both data sets, an 
increase in triple-negative subtypes in the Curtis data 
set and distant metastasis, and poor long-term metasta-
sis-free survival in the Hatzis data set (Supplementary 
information, Table S3 and Figure S4D). Thus a high 
number of TI naive CD4+ T cells are associated with 
poor prognosis. 
Naive CD4+ T cells convert to functional Tregs in a 
breast cancer microenvironment in vitro
Our data so far suggest that naive CD4+ T cells may 
differentiate into Tregs within breast tumors. Dendritic 
cells (DCs) have been shown to induce naive T cell con-
version into Tregs in the presence of cancer cell-secret-
ed immunomodulators [19, 20]. To determine whether 
naive CD4+ T cells can develop into Tregs in the tumor 
microenvironment [13], we co-cultured naive CD4+ T 
cells, isolated from the PB of breast cancer patients, with 
autologous plasmacytoid DCs (pDCs), isolated from the 
blood or breast cancer tissues in normal culture medium 
or medium that was supplemented with 30% conditioned 
medium (CM) from autologous cancer tissue slices (Fig-
ure 3A and 3B). TI pDCs, but not PB pDCs, converted 
7.5% ± 1.7% of naive CD4+ T cells to CD25+Foxp3+ 
Tregs in unsupplemented medium. Tumor CM on its own 
without DCs did not induce Treg differentiation of naive 
CD4+ T cells, but PB pDCs caused Treg differentiation 
when tumor CM was added. However, the greatest effect, 
23.2% ± 3.4% Tregs, was seen when both TI pDCs and 
tumor CM were added. The co-cultures that increased the 
numbers of Tregs, defined by CD25 and Foxp3 expres-
sion, also increased the mRNA expression of Treg-asso-
ciated genes, TGFB1, CTLA4, IL10 and GITR by quan-
Figure 1 The TCR repertoire of breast cancer tumor-infiltrating Tregs is most similar to that of naive CD4+ T cells. (A-D) Full-
length TCR-β/α variable regions of Tregs, naive CD4+ T cells and memory CD4+ T cells from peripheral blood (PB), lymph 
nodes (LN) and primary tumors (tumor-infiltrating, TI) of five breast cancer patients were amplified and sequenced. Pooled 
data from all five patients were compared. (A) Experimental schematic. (B) Frequencies of Vα/β gene usage in the groups 
of isolated T cells (V genes were ordered based on decreasing frequency in PB naive CD4+ T cells). (C) Similarity of pooled 
TCR repertoires, calculated using the Morisita-Horn similarity index [16], was used to cluster the groups of T cells analyzed. 
A value between 0 (no similarity) and 1 (identical) was calculated and colored according to the shown scale. (D) Individual 
overlap sequences of TI Treg identified in other groups of T cells. Individual TCR sequences of TI Tregs were arrayed on the 
x axis and the relative frequency at which this particular sequence was found in other subsets was plotted on the y axis. (E) 
Proportion of unique TRBV12-4/TRBJ1-2 sequences shared between TI Tregs and the 3 PB T cell subtypes (Treg, naive and 
memory CD4 T cells) in 23 breast cancer patient samples (shown are proportion of overlapping sequences (mean ± SEM), 
***P < 0.001 by Student’s t-test).
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titative reverse transcription (qRT)-PCR (Figure 3C). 
Increases in expression of these genes were in proportion 
to the generation of CD25+Foxp3+ cells in the cultures, 
being greatest for naive cells cultured in the presence of 
both TI pDCs and CM. We observed similar results when 
myeloid DCs were substituted for pDCs (Supplementary 
information, Figure S5). 
To determine whether the Tregs converted from naive 
CD4+ T cells are functional immunosuppressor cells, we 
isolated CD25+CD127− Tregs from the co-cultures and 
evaluated their ability to suppress autologous CD8+ cyto-
toxic T lymphocytes (CTLs) (Figure 3D-3G). Adding the 
induced Tregs strongly inhibited proliferation of CTLs 
in response to tumor lysate-pulsed autologous DCs in 
proportion to the numbers of Tregs added (Figure 3D), 
and markedly reduced their perforin (Figure 3E) and 
granzyme B (Figure 3F) levels. CTL killing of autolo-
gous primary breast cancer cells, assessed by propidium 
iodide staining and loss of mitochondrial transmembrane 
potential, was significantly reduced after co-culture with 
the induced Tregs (Figure 3G). These in vitro-generated 
Tregs also similarly functionally suppressed tumor-as-
sociated antigen (Muc1)-specific CTLs, generated from 
CTLs by exposure to Muc1 peptide-incubated autolo-
gous DCs (Supplementary information, Figure S6). Thus 
naive CD4+ T cells can be converted to functional Tregs 
in vitro by exposure to TI DCs and tumor CM.
Breast cancers express more CCL18 than adjacent nor-
mal breast tissues
Our data suggest that naive CD4+ T cells are recruited 
from the blood to breast tumors, where they can differ-
entiate into immunosuppressive Tregs. Next we wanted 
to know the mechanism responsible for naive CD4+ T 
cell recruitment. As T cell migration is orchestrated by 
responses to chemokine gradients, we first compared the 
relative mRNA expression of a panel of chemokines to 
which naive T cells respond — CCL3, 4, 18, 19 and 21 
— in 52 breast cancers vs paired adjacent normal breast 
tissues. Of these chemokines, only CCL18 mRNA was 
significantly higher in breast cancer than the paired adja-
cent normal tissue (Figure 4A and Supplementary infor-
mation, Figure S7A). In five independent breast cancer 
online data sets, CCL18 mRNA was increased in the tu-
mor relative to normal tissue and significantly increased 
in two data sets (Supplementary information, Table S4). 
TAMs abundantly express CCL18 [21], a chemokine 
toward which naive T cells preferentially migrate [22]. 
In our samples, the mRNAs of CCL22 and CCL28, two 
chemokines to which Tregs can respond [4, 10], did not 
increase and CCL28 even decreased in tumor (Supple-
mentary information, Figure S7A). Significant changes in 
CCL22 and CCL28 in the online breast cancer data sets 
also showed decreased tumor expression (Supplementary 
information, Table S4), suggesting that these chemokines 
are unlikely to play an important role in Treg recruitment 
to breast cancer. Based on expression data, CCL18 is an 
attractive candidate chemokine for recruiting naive CD4+ 
T cells to breast tumors. 
CCL18, expressed on TAMs, preferentially recruits naive 
CD4+ T cells to breast tumors in vitro and in vivo 
To explore a potential role for CCL18, we used immu-
nofluorescence microscopy to examine whether CCL18 
expression on TAMs correlates with naive CD4+ T cells 
in tumors. 626 breast cancer samples were stained for 
CD3, CD4 and CD45RA to identify naive CD4+ T cells 
and for CD68 and CCL18 to identify CCL18+ TAMs 
(Figure 4B and 4C). The numbers of naive CD4+ T cells 
and CCL18+ TAMs were highly correlated (P < 0.0001). 
To determine whether CCL18+ TAMs could recruit naive 
T cells to tumors, we used a tumor slice assay in which 
freshly resected breast cancer slices were overlaid with 
autologous naive CD4+ T cells labeled with carboxyflu-
orescein succinimidyl ester (CFSE), and the number of 
stained CD4+ T cells bound was counted and compared 
to the numbers of CCL18+ TAMs in the tumor [23]. As 
controls, we treated slides from patients with DCIS. 
Figure 2 Naive CD4+ T cell abundance within breast tumors is associated with increased numbers of Tregs and poor pa-
tient prognosis. (A) IHC staining of CD3 (red) and CD45RA (brown) in a representative breast cancer sample. Naive T cells 
were defined as CD3+CD45+ cells. Scale bar, 50 µm. (B) Correlation of TI naive CD4+ T cell numbers and TI Treg numbers in 
breast cancer samples (n = 626, Pearson correlation coefficient R and P-value are shown). (C) Representative immunofluo-
rescent staining for naive T cells (CD3 (red), CD45RA (green) and CD4 (purple); upper panels) or Tregs (Foxp3 (green) and 
CD4 (purple); lower panels) in serial sections from a human breast cancer sample. Arrows indicate CD3+CD4+CD45RA+ naive 
CD4+ T cells (upper) and CD4+Foxp3+ Tregs (lower). Scale bar, 50 µm. The localization of naive CD4 T cells and Tregs rela-
tive to the perivascular space or tumor parenchyma for 626 tumor samples is provided in Supplementary information, Figure 
S3C. (D) Representative immunofluorescent staining of CD3 (red), CD45RA (green), CD4 (purple) and DAPI (blue) in breast 
cancer samples with high (upper panel) or low (lower panel) number of naive CD4+ T cells, which are indicated by arrows. 
Scale bar, 50 µm. (E) Kaplan-Meier survival curve of breast cancer patients with low and high numbers of TI naive CD4+ T 
cells. BV, blood vessel; TN, tumor nest.
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Naive CD4+ T cells adhered to the tumor slices in pro-
portion to the number of CCL18+ TAMs (Figure 4D). 
Significantly more naive CD4+ T cells adhered to all the 
cancer samples, even those with the least numbers of 
CCL18+ TAMs, compared to the DCIS samples. 
Next we wanted to determine whether CCL18+ TAMs 
recruit naive CD4+ T cells from the blood in vivo. MDA-
MB-231, a triple-negative breast cancer cell line, induces 
macrophages to produce CCL18 [24]. We therefore ex-
amined in vivo recruitment [25] of intravenously injected 
CFSE-labeled human normal donor naive CD4+ T cells 
into palpable mammary fat pad breast tumors in NOD/
scid mice, formed by MDA-MB-231 breast cancer cells, 
co-injected with or without human macrophages (Figure 
4E). Xenografts formed with macrophage co-injection 
showed increased naive CD4+ T cell infiltration. In some 
experiments the CD4+ T cells were co-injected with an-
ti-CCL18 or isotype-matched control antibody. Blocking 
CCL18 reduced CD4+ T cell localization to the xeno-
graft, almost to the level of xenografts that were formed 
without macrophage co-injection. Moreover, intratumoral 
injection of recombinant CCL18 in orthotopic xenografts 
formed without macrophages effectively substituted for 
the macrophages to promote naive CD4+ T cell recruit-
ment. Thus CCL18 expression by TAMs recruits naive 
CD4+ T cells to orthotopic breast cancer xenografts. It 
should be noted that there were no Foxp3+ Tregs in any 
of the xenografts (Supplementary information, Figure 
S7B) and no difference in tumor size among different 
groups (Supplementary information, Figure S7C). This 
finding is not unexpected, as human DCs, which prime 
the generation of Tregs, are absent from this model. 
To investigate whether CCL18 also recruits memory 
CD4+ T cells or Tregs, we repeated these experiments 
substituting intravenously injected memory CD4+ T cells 
or Tregs for the naive CD4+ T cells (Supplementary in-
formation, Figure S7D and S7E). Memory CD4+ T cell 
recruitment was not affected by macrophage co-injection 
or anti-CCL18, whereas Treg recruitment was enhanced 
by macrophage co-injection, but independently of 
CCL18. Moreover, recombinant CCL18 did not increase 
Treg chemotaxis in a transwell assay, whereas the known 
Treg migration mediator CCL22 did (Supplementary 
information, Figure S7F). Thus CCL18 expressed by 
TAMs selectively recruits circulating naive CD4+ T cells, 
but not memory or Treg CD4+ T cells, into breast cancer. 
However, incubation of naive healthy donor CD4+ T cells 
with CCL18 did not induce CD25 or Foxp3 expression 
or confer on them the ability to suppress the proliferation 
of autologous CD8+ T cells that were stimulated with 
MDA-MB-231 cell lysate-pulsed myeloid DCs (Sup-
plementary information, Figure S7G and S7H). Thus al-
though CCL18 induces migration of naive CD4+ T cells 
into tumors, it does not cause them to differentiate into 
Tregs. 
PITPNM3 mediates CCL18-induced chemotaxis of naive 
CD4+ T cells
Although CCL18 preferentially attracts naive T 
cells, its receptors on these cells remain unidentified. 
Figure 3 Naive CD4+ T cells are converted to functional Tregs by tumor-infiltrating DCs and tumor conditioned medium (CM). 
(A-C) Naive CD4+ T cells from peripheral blood of patients with invasive breast carcinoma were co-cultured with or without 
autologous pDCs isolated from tumor (TI) or peripheral blood (PB) for 9 days in the presence or absence of 30% CM from 
autologous tumor slices or adjacent normal tissue slices. (A, B) Non-adherent cells from co-cultures were stained for CD3, 
CD4, CD25 and intracellular Foxp3, and analyzed by flow cytometry. Representative plots of gated CD3+CD4+ cells (A) and 
quantification of percentage of Foxp3+CD25+ cells among CD3+CD4+ cells (B) are shown (mean ± SEM, n = 19; *P < 0.05, 
**P < 0.01,***P < 0.001 by Student’s t-test). (C) Expression of Treg-associated genes, assessed by qRT-PCR normalized to 
GAPDH, in sorted CD4+ T cells, relative to expression in cultures without DCs or CM (mean ± SEM, n = 19; *P < 0.05, **P < 
0.01,***P < 0.001 compared with naive CD4+ T cells cultured alone by Student’s t-test). (D-G) Effect of naive CD4+ T cell-de-
rived Tregs, obtained by co-culture with TI pDCs and tumor CM as above, on function of autologous tumor-specific CD8+ T 
cells. Tumor-specific CD8+ T cells were generated for each subject by stimulating autologous PB CD8+ T cells with autolo-
gous tumor lysate-pulsed autologous DCs. Tregs were recovered from co-cultures by magnetic sorting. (D) CFSE-labeled 
CD8+ T cells were incubated with tumor lysate-pulsed DCs in the presence of induced Tregs at the indicated ratios and pro-
liferation was assessed by flow cytometry. Numbers denote the percentage of cells undergoing at least one cellular division 
(mean ± SEM, n = 12, **P < 0.01, ***P < 0.001 compared with CD8+ T cells cultured without Tregs). (E-G) Tumor-specific 
CD8+ T cells were incubated with autologous primary breast cancer cells for 18 h in the presence or absence of Tregs (CD8:Treg 
2:1) and stained for CD3, CD8, intracellular perforin (E) or granzyme B (F) and gated CD3+CD8+ cells were analyzed by flow 
cytometry. Numbers indicate the percentage of gated cells stained for perforin or granzyme B (mean ± SEM, n = 7; ***P < 0.001 
compared with CD8+ T cells cultured without Tregs). (G) Tumor-specific CD8+ T cells were incubated with autologous diocta-
decyloxacarbocyanine (DIOC18)-labeled primary breast cancer cells for 18 h in the presence or absence of Tregs (CD8:Treg 
2:1) and the death of tumor cells was assessed by propidium iodide (PI) uptake by flow cytometry. The numbers shown indi-
cate the percentage of PI+ tumor cells (mean ± SEM, n = 4; ***P < 0.001 compared with CD8+ T cells cultured without Tregs).
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Figure 4 Naive CD4+ T cells are recruited to breast tumors by TAM-secreted CCL18. (A) CCL18 expression in breast cancer 
tissues and paired adjacent normal breast tissues detected by qRT-PCR relative to GAPDH (n = 52; ***P < 0.001 by Stu-
dent’s t-test). (B) Correlation of numbers of CCL18+ TAM (CD68+CCL18+) and naive CD4+ T (CD3+CD4+CD45RA+) cells in 
breast cancer samples (n = 626, Pearson’s correlation coefficient R and P-value are shown). (C) Representative immunoflu-
orescent staining for CD68 and CCL18 and CD3, CD45RA and CD4 from CCL18-high (upper panel) and CCL18-low (lower 
panel) breast cancer samples. CCL18+ TAMs and naive CD4+ T cells are indicated by arrows. Asterisk indicates the location 
of higher magnification images at right. Scale bar, 50 µm. (D) Naive PB CD4+ T cells labeled with CFSE (green) were overlaid 
on autologous breast tumor slices that were then fixed and stained for CCL18 (red). Representative images (left) and quantif-
470
Blocking naive CD4+ T cells reverses immunosuppression
SPRINGER NATURE | Cell Research | Vol 27 No 4 | April 2017
PITPNM3 and CCR8 are reported CCL18 receptors on 
breast cancer cells and Th2 cells, respectively [21, 26]. 
Moreover, a recent report showed that CCR8 is selective-
ly overexpressed on TI Tregs, compared to normal tissue 
and PB Tregs [12]. Therefore, we examined the expres-
sion of PITPNM3 and CCR8 in T cell subsets from PB 
of breast cancer patients. CCR8 was only weakly ex-
pressed in naive T cell populations, but was more highly 
expressed on circulating Tregs and a subpopulation of 
memory CD4+ T cells (Figure 5A and Supplementary 
information, Figure S8A). In contrast, PITPNM3 was 
highly expressed by most naive CD4+ and CD8+ T cells 
(Figure 5A and Supplementary information, Figure S8A-
S8D) in agreement with a previous report that CD4+ and 
CD8+ naive T cells respond to CCL18 [22], and more 
weakly on memory T cells. TI naive CD4+ T cells also 
had uniformly high PITPNM3 expression, but PB Tregs 
had low PITPNM3 expression. Based on these expres-
sion data, it is likely that PITPNM3, rather than CCR8, 
is the chemokine receptor on naive CD4+ T cells that re-
sponds to CCL18. 
To investigate whether PITPNM3 mediates CCL18 
binding on naive CD4+ T cells, we first assessed binding 
of 125I-CCL18 (Figure 5B). CCL18 specifically bound to 
naive CD4+ T cells with low nanomolar affinity (Ki = 6.5 
nM, 5.8-7.3 nM, 95% confidence interval), and binding 
was competed by unlabeled CCL18. Moreover, knock-
ing down PITPNM3 by infecting naive CD4+ cells with 
a lentivirus expressing a PITPNM3 shRNA markedly 
inhibited 125I-CCL18 binding. Immunofluorescence mi-
croscopy using CCL18 and PITPNM3 antibodies showed 
that CCL18 co-localized with PITPNM3 on the surface 
of naive CD4+ T cells, which was abrogated by PIT-
PNM3 knockdown (Figure 5C). Furthermore, CCL18-in-
duced Akt and Erk phosphorylation (Figure 5D), calcium 
influx (Figure 5E) and migration (Figure 5F) of naive 
CD4+ T cells were attenuated by PITPNM3 knockdown. 
Thus, PITPNM3 is a CCL18 receptor on naive CD4+ T 
cells.
PITPNM3 knockdown in naive CD4+ T cells in vivo 
blocks their recruitment to tumors and Treg infiltration, 
reverses immunosuppression and inhibits tumor progres-
sion in humanized mice
Our data thus far suggest that breast TI Tregs devel-
op from naive CD4+ T cells that are recruited to tumors 
when their PITPNM3 receptor recognizes CCL18 secret-
ed by TAMs. To confirm the role of PITPNM3 in naive 
CD4+ T cell recruitment to breast tumors and elucidate 
the role of naive CD4+ T cell infiltration in Treg gen-
eration and cancer progression in vivo, we employed a 
humanized mouse tumor model. NOD/SCID/IL2rγnull 
(NSG) mice were first transplanted with human fetal thy-
mus and hematopoietic cord blood (CB) cells, and then 
inoculated in the mammary fat pad with MDA-MB-231 
breast cancer cells (Supplementary information, Figure 
S9A). Gene expression can be efficiently and selec-
tively knocked down in CD4+ cells in vivo by injecting 
CD4-aptamer-siRNAs chimeras (AsiC) (Figure 6A), 
RNAs composed of a CD4 aptamer linked to an siRNA 
[27]. We designed CD4-AsiCs to knock down PITPNM3 
(CD4-AsiC-PI) or a non-targeting control siRNA (CD4-
AsiC-con). Once tumors became palpable, we injected 
these CD4-AsiCs intraperitoneally and verified by west-
ern blot and qRT-PCR that PITPNM3 was selectively 
knocked down by the CD4-AsiC-PI, but not by the CD4-
AsiC-con, in CD4+ T cells, but not in MDA-MB-231 
cells (which also express PITPNM3) (Figure 6B and 
Supplementary information, Figure S9B). Injection of 
AsiC-PI did not alter human leukocyte reconstitution in 
the mice (Figure 6C). We next assessed by immunoflu-
orescence microscopy and flow cytometry whether PIT-
PNM3 knockdown in CD4+ cells alters the numbers of 
types of CD4+ and CD8+ T cells in the xenografts (Figure 
6D-6F, Supplementary information, Figure S9C). Mice 
that received CD4-AsiC-PI had significantly fewer naive 
CD4+ T cells and Tregs and more CD8+ T cells in the tu-
mors compared to mice that received PBS or CD4-AsiC-
con. The overall numbers of CD4+ cells in the tumor was 
not significantly different since there were more memory 
CD4+ T cells in the CD4-AsiC-PI-treated mouse tumors. 
Moreover, the number of human naive CD4+ T cells and 
Tregs were strongly correlated (P < 0.0001; Supplemen-
tary information, Figure S9D). The Tregs isolated from 
the tumors were functional, as they suppressed the pro-
liferation of autologous PB CD8+ T cells stimulated with 
ication of number of adherent CFSE+ T cells (mean ± SEM; right) are shown (ductal carcinoma in situ (DCIS), n = 4; invasive 
cancer with CCL18+ cell count < 5, n = 9; 5-20, n = 6; > 20, n = 4; *P < 0.05; ***P < 0.001 by Student’s t-test). Scale bar, 50 
µm. (E) CFSE-labeled PB naive CD4+ T cells from healthy donors were intravenously injected via tail vein, with or without 
control IgG or CCL18-neutralizing antibody, into NOD/scid mice bearing subcutaneous MDA-MB-231 breast cancers that 
were implanted 14 days earlier either alone or with autologous human macrophages. In some mice, the xenografts were in-
jected with rhCCL18. The number of CFSE+ T cells that migrated into the xenografts was measured by immunofluorescence 
microscopy 48 h after T cells were injected. Shown are representative images (left) and the number of CFSE+ cells/high pow-
er field for each condition (mean ± SEM, n = 8 mice per group. **P < 0.01; ***P < 0.001 by Student’s t-test). Scale bar, 50 µm. 
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anti-CD3 and anti-CD28 (Supplementary information, 
Figure S9E). However, human Tregs were rare in the 
PB of the humanized mice (Supplementary information, 
Figure S9F), suggesting that Tregs were converted from 
naive CD4+ T cells in tumors. The reduction in TI Tregs 
and increase in TI CD8+ T cells were associated with 
more apoptosis in the tumor (Figure 6D and 6E). Mice 
treated with CD4-AsiC-PI also showed significantly 
smaller primary tumors and attenuated lung metastases 
(Figure 6G-6J). Thus knocking down PITPNM3 in CD4+ 
cells reduced TI Tregs and enhanced TI CD8+ T cells, 
promoting anti-tumor immunity and tumor control. Of 
note, mice treated with CD4-AsiC-PI showed no signifi-
cant signs of toxicity (Supplementary information, Table 
S5).
Because human PB Tregs were rare in the tumor-bear-
ing humanized mice, to better mimic human breast 
cancer and determine whether PB Tregs infiltrate the 
tumors, we adoptively transferred autologous Tregs, 
expanded ex vivo from CB as previously described [28, 
29], 6 weeks after the transplant of hematopoietic stem 
cells (HSCs) at the time of concomitant tumor implan-
tation and every 10 days thereafter in the humanized tu-
mor model described above. The transferred Tregs were 
labeled with CFSE (Figure 7A). After transfer, Foxp3+ 
Tregs accounted for about 4% of human PB CD4+ T cells 
(Figure 7B and 7C). Most of the PB Tregs were CFSE 
labeled, indicating that they were mainly adoptively 
transferred. When the tumors became palpable, the mice 
were injected intraperitoneally with PBS, CD4-AsiC-
con or CD4-AsiC-PI. AsiC treatment did not affect the 
number of PB Tregs (Figure 7C). In the control mice 
given PBS or CD4-AsiC-con, Tregs accounted for about 
30% of TI CD4+ T cells and most of these were CFSE− 
(Figure 7D and 7E). The proportion of TI Tregs in the 
adoptively transferred mice was similar to that in the 
humanized mice that did not receive transferred Tregs 
(compare Figure 6F, Figure 7D-7E). These data, together 
with the paucity of CFSE-stained Tregs in the tumors 
from adoptively transferred mice, strongly suggest that 
TI Tregs were mainly derived from recruited naive CD4+ 
T cells, rather than from circulating Tregs. In fact, in the 
adoptively transferred tumor-bearing mice, knockdown 
of PITPNM3 by CD4-AsiC-PI in CD4+ T cells markedly 
reduced CFSE− TI Tregs, but had no effect on the small 
number of TI CFSE+ Tregs (Figure 7D and 7E). As be-
fore, CD4-AsiC-PI treatment dramatically reduced tumor 
growth and lung metastasis in the adoptively transferred 
tumor-bearing mice (Figure 7F and 7G). Together, these 
results suggest that Tregs are generated from naive CD4+ 
T cells responding via PITPNM3 to CCL18 produced in 
the tumor. They also suggest that interfering with PIPT-
NM3 or CCL18 could be used therapeutically to enhance 
anti-tumor immunity in breast cancer.
Discussion
Although it is well documented that TI Tregs suppress 
the protective immune response to cancer, the origin of 
TI Tregs remains unclear [1, 3, 9]. In principle TI Tregs 
could arise from recruitment of circulating Tregs primed 
in the thymus or in peripheral LNs or from recruited 
naive or memory CD4+ T cells that are converted to 
Tregs in tumors [1, 3, 9]. Our results suggest that Tregs 
in human breast cancer are mainly converted from naive 
PB CD4+ T cells, recruited by TAM-derived CCL18. 
To build this case, we showed that CD4+ naive T cells 
are abundant in the stroma of extensively perfused 
samples — close to, but not within blood vessels — in 
most breast tumors compared to adjacent normal tissue; 
that their abundance correlates with TI Treg numbers; 
that the clonotypic TCR sequences of TI naive CD4+ 
Figure 5 PITPNM3 is a CCL18 receptor on naive CD4+ T cells. (A) Representative flow cytometry staining for PITPNM3 and 
CCR8, potential CCL18 receptors, on gated PB T cell subsets and paired TI naive CD4+ T cells of a breast cancer patient. 
Cells were gated on CD3+CD45RA+CD45RO−CD25−CD4+/CD8+ for naive CD4+/CD8+ T cells, CD3+CD45RA−CD45RO+CD25−
CD4+/CD8+ for memory CD4+/CD8+ T cells and CD3+CD4+CD25+ for Tregs). Quantitation of PITPNM3 and CCR8 expression 
on T cell subsets for eight breast cancer patients is provided in Supplementary information, Figure S8A. (B-F) Knockdown of 
PITPNM3 in naive CD4+ T cells inhibits CCL18 binding, signaling and chemotaxis. (B) Binding of 125I-CCL18 to naive CD4+ T 
cells, knocked down or not for PITPNM3 (shPI-1,2) in the presence of increasing concentrations of unlabeled CCL18. Shown 
are the representative assays for three independent experiments using PB T cells from three normal donors. (C) Represen-
tative fluorescence microscopy images of CCL18 binding to naive CD4+ T cells, knocked down or not for PITPNM3, stained 
for PITPNM3 and CCL18 3 h after adding CCL18. Scale bar, 5 µm. Shown are the representative images for three indepen-
dent experiments using PB T cells from three normal donors. (D) Immunoblot of CCL18-treated naive CD4+ T cells, knocked 
down or not for PITPNM3, showing expression of PITPNM3 and phosphorylated/total (t-) Erk1/2 and Akt, relative to GAPDH 
as a loading control. Blots are representative of data for three donors. (E) Blunted [Ca2+]i mobilization in CCL18-treated naive 
CD4+ T cells knocked down for PITPNM3. Data are representative tracings for three donors. (F) Blunted chemotaxis of naive 
CD4+ T cells to CCL18 in a transwell assay. Data are shown as mean ± SEM. Chemotaxis indices for three independent ex-
periments (**P < 0.01 by Student’s t-test).
Shicheng Su et al.
473
www.cell-research.com | Cell Research | SPRINGER NATURE
474
Blocking naive CD4+ T cells reverses immunosuppression
SPRINGER NATURE | Cell Research | Vol 27 No 4 | April 2017
T cells, rather than PB Tregs or TI memory T cells, are 
most similar to that of TI Tregs; and that the abundance 
of naive CD4+, but not CD8+, T cells in tumors is an in-
dependent negative prognostic factor for breast cancer. 
We then showed that naive CD4+ T cells from the PB 
of breast cancer patients differentiate in vitro into func-
tional Tregs by exposure to autologous DCs and CM 
from their tumors. Although migration of naive T cells 
to peripheral lymphoid organs is mediated by CCL19 
and CCL21 [30], migration of these cells to tumors is 
independent of these chemokines [31]. We implicated 
CCL18, previously identified as a breast cancer TAM-se-
creted chemokine [21, 24], in recruiting naive CD4+ T 
cells into breast tumors by binding to the chemokine 
receptor PITPNM3. Our evidence was that CCL18 was 
the only candidate chemokine overexpressed in human 
breast tumors relative to adjacent normal tissues; the 
abundance of TI naive CD4+ T cells correlated strongly 
with the abundance of CCL18+ TAMs; migration of PB 
naive CD4+ T cells into autologous tumor tissue slices 
correlated with the numbers of CCL18+ TAMs in the 
tumor; PITPNM3, but not CCR8 (another receptor for 
CCL18), was highly expressed by PB and TI naive CD4+ 
T cells compared to Tregs; CCL18 colocalized with PIT-
PNM3 and its binding, signaling and chemotactic effect 
on naive CD4+ T cells was suppressed by PITPNM3 
knockdown. Most importantly, this model was validated 
in mouse models. Adoptively transferred human naive 
CD4+ T cells were recruited to orthotopic MDA-MB-231 
triple-negative breast cancer tumors in NOD/scid mice 
and the recruitment was greatly enhanced by co-implan-
tation of human macrophages and was dependent on 
CCL18, as it was suppressed by injection of anti-CCL18 
(Figure 4E). We also tested this model in tumor-bearing 
mice transplanted with human HSCs and fetal thymus 
that develop a human immune system (Figures 6 and 7). 
Systemic and selective knockdown of PITPNM3 in CD4+ 
T cells achieved by intraperitoneal injection of CD4-
AsiCs blocked recruitment of TI naive CD4+ T cells and 
development of TI Tregs, caused expansion of TI CD8+ T 
cells and increased intratumoral apoptosis, and strongly 
suppressed primary tumor growth and metastases. 
Naive T cells were previously thought to traffic exclu-
sively to lymphoid organs. Growing evidence suggests 
that this viewpoint is too simplistic [32, 33]. First, it is 
well documented that naive T cells can enter non-lym-
phoid organs that contain tertiary lymphoid structures [33-
35]. More recent reports also indicate that naive T cells 
can enter non-lymphoid organs in the absence of lym-
phoid structures. Naive T cells have been found in many 
non-lymphoid organs, especially in the lungs, as part of 
normal migratory pathways in normal mice [36, 37], and 
in inflamed tissues [38] and in tumors [31, 39] of mice. 
Moreover, the presence of naive CD4+ T cells has been 
previously noted in human breast cancer [40], although 
their role and significance were not previously explored.
Our findings in human samples are in agreement with 
previous reports that Tregs in murine breast cancers are 
derived from resting CD4+ T cells [41, 42]. Previous 
studies in mouse or human ovarian cancers suggested 
that TI Tregs could be recruited from the circulation to 
tumors by CCL22 and CCL28. However, CCL22 and 
CCL28 expression is not increased in human breast 
cancers compared to normal breast tissue, making them 
unlikely Treg recruiters to human breast cancer. Differ-
ent cytokine expression profiles in different cancer types 
Figure 6 In vivo knockdown of PITPNM3 in CD4+ T cells reverses immunosuppression and inhibits tumor progression in hu-
manized mice. (A) Humanized mice bearing palpable MDA-MB-231 orthotopic xenografts were intraperitoneally injected daily 
for 14 days with PBS, 1 nmol CD4-aptamer-control siRNA (AsiC-con) or CD4-aptamer-siRNA targeting PITPNM3 (sequence 
in A, AsiC-PI) to assess the role of PITPNM3 in TI Tregs, and other T cells and tumor control. Experimental schematic is 
provided in Supplementary information, Figure S9A. (B) Representative immunoblots showing selective knockdown of PIT-
PNM3 protein in PB CD4+ T cells, but not tumor xenografts (n = 3). (C) PITPNM3 knockdown did not affect the distribution of 
human CD45+ hematopoietic cells, CD4+ and CD8+ T cells, and CD14+ monocytes in the peripheral blood of humanized mice. 
Representative flow plots are shown (n = 3). (D, E) Effect of PITPNM3 knockdown on TI naive CD4+, Tregs and CD8+ T cell 
numbers, and apoptosis by TUNEL assay in xenografts. D shows representative immunofluorescence microscopy images. 
Top row indicates CD4+ naive T cells by arrows; the second row indicates CD4+CD45RO+Foxp3−CD4+ memory T cells (yel-
low arrows) and Foxp3+ Tregs (white arrows). Scale bar, 50 µm. E shows number of cells of each subtype/high power field in 
eight mice (**P < 0.01, ***P < 0.001 compared to PBS group by Student’s t-test). (F) Flow cytometry analysis of gated human 
CD3+CD4+ cells isolated from xenografts stained for CD127 and Foxp3. Representative flow plots in each group were shown. 
Numbers show the proportion of Tregs for eight mice per group (mean ± SEM; ***P < 0.001 compared to PBS group by Stu-
dent’s t-test). (G) Representative bioluminescence imaging of primary tumor and metastases in mice. (H) Primary tumor size 
(mean ± SEM) in each treatment group (8 mice per group; ***P < 0.001 by two-way ANOVA with Bonferroni multiple compari-
son tests). (I) Representative lung IHC images stained for human cytokeratin to identify human cancer cell metastases. Scale 
bar, 50 µm. (J) Quantification of metastatic lung tumors by qRT-PCR analysis of human HPRT mRNA relative to mouse 18S 
rRNA. Data are shown as mean ± SEM for eight mice per group (**P < 0.01 by Student’s t-test).
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Figure 7 CD4-aptamer-siRNA targeting PITPNM3 reduces TI Tregs and inhibits tumor progression in humanized mice with 
circulating human Tregs. Humanized mice, implanted with MDA-MB-231 tumors and concurrently injected intravenously with 
autologous Tregs, were intraperitoneally injected daily for 14 days after tumors became palpable with PBS, 1 nmol CD4-ap-
tamer-control siRNA (AsiC-con) or CD4-aptamer-siRNA targeting PITPNM3 to assess the role of PITPNM3 in TI Tregs, and 
other T cells and tumor control. Tregs were administered every 10 days after the initial injection and mice were sacrificed 30 
days after tumor cell inoculation. (A) Experimental schematic. (B, C) Peripheral blood cells of humanized mice were stained 
for human CD3, CD4 and Foxp3, and analyzed by flow cytometry. A representative flow plot (B) and the percentage (mean ± 
SEM) of PB CD4+ cells that are CFSE+ Tregs in six mice per group (C) are shown. (D, E) Isolated cells from xenografts were 
stained for human CD3, CD4 and Foxp3. The percentage (mean ± SEM) of six mice per group (D) and representative flow plot (E) 
of FoxP3+ Tregs are shown. Most Tregs were CFSE− (i.e., did not come from infused Tregs) and the number of TI Tregs was 
reduced by knocking down PITPNM3 in CD4+ T cells (***P < 0.001 compared to the PBS group by Student’s t-test). (F) Tumor 
size (mean ± SEM, n = 6 per group; ***P < 0.001 by two-way ANOVA with Bonferroni multiple comparison tests). (G) Lung me-
tastases assessed by qRT-PCR analysis of human HPRT mRNA relative to mouse 18S rRNA in the lungs. Data are shown as 
mean ± SEM (n = 6 per group; **P < 0.01 by Student’s t-test). NS, not statistically significant by Student’s t-test.
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may lead to distinct sources of TI Tregs. Future research 
will need to determine to which other types of tumors 
our model of TI Treg development from recruited naive 
T cells applies.
A recent study found that the TCR repertoire of TI 
Tregs showed low overlap with that of normal breast tis-
sue or PB Tregs or TI effector (CD25−) T cells [12]. Their 
results, in agreement with ours, suggest that TI Tregs 
do not arise from either recruitment of Tregs from the 
periphery or from conversion of activated conventional 
T cells within the tumor, in agreement with our model. 
However, that study did not compare the repertoires of 
Tregs with PB or TI naive CD4+ T cells and hence did 
not address whether Tregs might arise from recruited 
PB naive CD4+ T cells. Our TCR sequence analysis 
also showed that the TCRs of TI memory CD4+ T cells 
overlapped with TCR sequences of PB and LN effector/
memory CD4+ T cells, and LN naive CD4+ T cells. Our 
results, therefore, suggest that tumor-reactive effector 
CD4+ T cells are primed in LNs. Therefore, generation of 
anti-tumor effector T cells and TI Tregs involve different 
chemokine responses and priming locations. It is possi-
ble to take advantage of these differences to reduce Treg 
progenitors without interfering with, or even (as our data 
suggest) boosting anti-tumor immunity.
Although CCR8 and PITPNM3 were identified as po-
tential CCL18 receptors on other cells [21, 26], the CCL18 
receptor in naive T cells was not known. In agreement 
with a previous report [43], we did not find that naive T 
cells express CCR8. In contrast, PITPNM3 is highly ex-
pressed in naive CD4+ T cells and mediates their CCL18 
binding and signaling. However, a large fraction of Tregs 
and memory T cells express CCR8, which might recruit 
them to breast tumors (Figure 5A). Besides chemokine 
receptors, other regulatory factors mediate lymphocyte 
chemotaxis to chemokine gradients, including regulator 
of G-protein signaling [44]. Overexpression of RGS1, 
RGS9 and RGS16 in Tregs, compared to naive CD4+ T 
cells, accounts for their distinct response to CCL19 and 
CCL21 in mice [45]. It is worth investigating whether 
differential expression of chemokine receptors together 
with RGS or other regulatory factors affects the chemo-
taxis of Tregs, and naive and effector CD4+ T cells to 
CCL18 secreted in tumors. 
A previous study showed that TI Tregs rapidly recover 
after they are depleted from tumor-bearing mice [42]. 
Our finding here suggests that inhibiting the in situ gen-
eration of TI Tregs might be a better strategy for cancer 
immunotherapy than depleting TI Tregs. Depletion of 
TI Tregs also carries the risk of systemic autoimmunity, 
unless TI Tregs can be selectively depleted without elim-
inating tissue Tregs. A recent study found that CCR8 is 
highly expressed by TI Tregs and not by PB Tregs, and 
suggested the therapeutic use of anti-CCR8 to selectively 
deplete TI Tregs [12]. However, Tregs in normal breast 
tissue also highly express CCR8 (about half as much as 
in tumors), suggesting that normal tissue Tregs might 
also be depleted. Experiments in immunocompetent 
mice, such as in the tumor-bearing humanized mouse 
model we used here or in genetically engineered mouse 
models of cancer, might determine whether depleting 
CCR8+ cells is safe and effective, and could be used to 
compare different approaches to control Treg suppression 
of tumor immunity.
In this study we showed that inhibiting naive CD4+ 
T cell recruitment by knocking down PITPNM3 in tu-
mor-bearing humanized mice could reduce TI Tregs, 
restore immune killing of tumors and suppress tumor 
growth and metastases, confirming the role of PITNM3 
recognition of CCL18 in TI Treg biogenesis. To achieve 
in vivo knockdown, we intraperitoneally injected CD4-
AsiCs targeting PITPNM3 and showed that they selec-
tively knock down gene expression in CD4+ T cells, but 
not in tumors. Previously topical administration of CD4-
AsiCs was used to knock down genes in human CD4+ 
T cells, without activating the cells or inducing innate 
immunity, in the genital tract of humanized mice to pre-
vent HIV transmission [27]. Our unpublished data also 
show that subcutaneous injection of CD4-AsiCs leads 
to systemic and selective in vivo gene knockdown in 
CD4+ cells. Thus CD4-AsiCs provide a valuable tool to 
interrogate the role of individual gene products in CD4 
cells in immune protection and pathology in general and 
in tumor immunity in particular that could potentially be 
developed for therapeutic use.
Inhibiting naive T cell recruitment into tumors by 
interfering with the CCL18-PITPNM3 interaction is a 
previously unappreciated potential strategy for tumor im-
munotherapy. It is dually beneficial — it not only inhibits 
the numbers of immunosuppressive Tregs in the tumor, 
but also increases the numbers of intratumoral protective 
effector CD8+ T cells, presumably because they are not 
suppressed from proliferating in response to the tumor. 
It is worth noting that neutralizing CCL18 has no appre-
ciable effect on tumor growth in NOD/scid mice bearing 
orthotopic breast tumors, which are not “humanized”, 
i.e., reconstituted with human immune cells (Supplemen-
tary information, Figure S5B). The difference between 
that model and the humanized mice indicates that tumor 
suppression was mediated by enhancing specific anti-tu-
mor immunity. In the future it will be worth examining 
in tumor-bearing humanized mice whether blocking 
CCL18 or PITPNM3 also leads to enhanced anti-tumor 
immunity and tumor suppression, and to compare it with 
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anti-CCR8 and with CD4-AsiCs against PITPNM3 or 
CCR8. In this study, CD4-AsiCs against PITPNM3 did 
not affect PB T cell subset numbers or lead to any ap-
parent toxicity in humanized mice. The safety and lack 
of autoimmunity secondary to CD4-AsiC knockdown of 
PITPNM3 or antibody inhibition of CCL18, PITPNM3 
or CCR8 will need to be examined carefully to evalu-
ate potential therapeutic applications. Nevertheless, our 
study suggests that blocking naive CD4+ T cell recruit-
ment and conversion to Tregs in tumors could be an at-
tractive new immune therapeutic strategy for cancer.
Materials and Methods
Primary cell isolation from breast cancer and blood
Primary cells were obtained from blood and tissues as previous-
ly described [4, 24]. Briefly, tumor tissues and LN obtained from 
ipsilateral axillary LN dissection were exhaustively perfused with 
PBS, minced into small (1-2 mm in diameter) pieces and digested 
with 5% FBS DMEM containing 2 mg/ml collagenase I and 2 mg/
ml hyaluronidase (Sigma) at 37 oC for 2 h and 0.5 h, respectively. 
The cells were sequentially filtered through 500 µm mesh, 100 and 
70 µm cell strainers, and then centrifuged in a Beckman Allegra 
X-15R centrifuge at 2 500 rpm for 20 min with 1 ml cell suspen-
sion above 5 ml 45% Percoll (GE Healthcare) in the middle and 5 
ml 60% Percoll at the bottom in a 15-ml tube. Primary tumor cells 
were collected from the cell layer in the interface above 45% Per-
coll and further purified by Cancer Cell Isolation Kit (Panomics). 
Mononuclear cells were collected from the cell layer at the inter-
face between 45% and 60% Percoll. Mononuclear cells from LN 
or 50 ml PB were also isolated by Ficoll density gradient centrifu-
gation. Naive CD4+ T cells, Tregs, memory CD4+ T cells, CD8+ T 
cells, pDCs or myeloid DCs were purified using the Naive CD4+ 
T Cell Isolation kit (130-094-131, Miltenyi), CD4+CD25+CD127− 
Regulatory T Cell Isolation Kit (130-094-775, Miltenyi), Memory 
CD4+ T Cell Isolation Kit (130-091-893, Miltenyi), CD8+ T Cell 
Isolation kit (130-094-156, Miltenyi), Diamond Plasmacytoid 
Dendritic Cell Isolation Kit (130-097-240, Miltenyi) and CD1c 
(BDCA-1)+ Dendritic Cell Isolation Kit (130-090-506, Miltenyi), 
respectively. The Tregs in naive/memory CD4+ T cells were de-
pleted using CD25 microbeads (130-092-983, Miltenyi). Cell pop-
ulations were confirmed to be > 90% pure by FACS.
TCR sequencing
For all T cell subsets, equal numbers of purified cells from each 
patient (~5-20 × 104) were used for TCR sequencing. TCR-β/α 
variable region full-length sequencing was performed as previous-
ly described [50, 51] with slight modifications. Total RNA was ex-
tracted and purified from T cell samples using ReliaPrep RNA Cell 
Miniprep System (Z6011, Promega), and was reverse transcribed 
into first-strand 5′RACE-ready cDNA by using SMARTer RACE 
5′/3′Kit (634859, TaKaRa) to add universal adapters at the 5′-end 
of the RNA and 3′-end of the cDNA. First round 5′RACE PCR 
was performed using Advantage 2 Polymerase (Clontech) with 
10× Universal Primer Mix (UPM, Clontech) and forward primer, 
and self-designed TCR constant region first round reverse primers 
(TCR: 5′-GGTGTCTTCTGGAATAATGCTGT-3′, TCR: 5′-GCT-
CAGGCAGTATCTGGAGTCATTG-3′). Amplification was per-
formed on a Applied Biosystems Veriti Thermal Cycler using the 
following conditions: 1 min at 95 °C; 5 cycles of 20 s at 95 °C 
and 30 s at 72 °C; 5 cycles of 20 s at 95 °C, 30 s at 70 °C and 30 
s at 72 °C; 25 cycles of 20 s at 95 °C, 30 s at 60 °C and 30 s at 72 
°C; and 5 min at 72 °C. Agarose gel-purified PCR products were 
then amplified (Semi-nested PCR) with Nested Universal Primer A 
forward primer (Clontech) and self-designed second round reverse 
primers (TCRα constant region: 5′-CAGGGTCAGGGTTCTG-
GAT-3′, TCRβ: 5′-CACAGCGACCTCGGGTGGGAA-3′). Am-
plification conditions were: 1 min at 95 °C; 30 cycles of 20 s at 95 
°C, 30 s at 60 °C and 30 s at 72 °C; and 5 min at 72 °C. Agarose 
gel-purified libraries were bar coded with multiplex adaptors and 
sequenced on Illumina MiSeq. The sequences of sample barcodes 
employed for multiplexing are given in Supplementary informa-
tion, Table S6. For TRBV12-4/TRBJ1-2 sequencing, we ampli-
fied clonotypes using adaptor-ligated barcode primers listed in 
Supplementary information, Table S6. Agarose gel-purified PCR 
products were sequenced using Ion Personal Genome Machine 
(PGM) system (ThermoFisher). The Sequence Read Archive (SRA) 
database (www.ncbi.nlm.nih.gov/sra/) accession number for the 
TCR sequences reported in this paper is SRP065925. The similar-
ity between the different TCR repertoires was calculated by the 
Morisita-Horn similarity index, which takes into account not only 
the number of shared sequences between two repertoires but also 
the contribution of those shared sequences to each repertoire [16].
Patients and tissue samples
Primary breast carcinomas were obtained from 481 patients at 
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University (Guang-
zhou, China) and 145 patients at the First Affiliated Hospital, 
Shantou University Medical College (Shantou, China). Benign 
breast tissue samples from 59 cases of cystic fibrosis with or with-
out atypical epithelial hyperplasia and tumor samples from 39 cas-
es of DCIS were collected at Sun Yat-Sen Memorial Hospital. All 
samples were collected with informed consent with the approval of 
the Internal Review and Ethics Boards of the indicated hospitals.
IHC and immunofluorescent staining of tissue
Antigen retrieval was performed by incubating slides in a 
pressure cooker for 5 min in 0.01 M citrate buffer (pH 6.0), fol-
lowed by treatment with 3% hydrogen peroxide for 5 min. Slides 
were incubated overnight at 4 °C with the following antibodies: 
CD3 (Cat# M7254, mouse anti-human, DAKO; 1:100 or Cat# sc-
1128, goat anti-human, Santa Cruz; 1:50), CD45RA (Cat# M0754, 
mouse anti-human, DAKO; 1:50), CD4 (Cat# PA5-11582, rabbit 
anti-human, Thermo Fisher Scientific; 1:100 or Cat# ab34276, rat 
anti-human, Abcam; 1:20), Foxp3 (Cat# ab20034, mouse anti-hu-
man, Abcam; 1:50 or Cat# ab54502, rabbit anti-human, Abcam; 
1:50), CD8 (Cat# MA5-14548, rabbit anti-human, Thermo Fisher 
Scientific; 1:200), CD45RO (Cat# M0742, mouse anti-human, 
DAKO; 1:200), CD62L (Cat# ab135792, rabbit anti-human, Ab-
cam; 1:50), CD20 (Cat# ab78237, rabbit anti-human, Abcam; 
1:100), CD68 (Cat# sc-7083, goat anti-human, Santa Cruz; 1:100), 
CCL18 (Cat# MAB394, mouse anti-human, R&D; 20 µg/ml) or 
human cytokeratin (Cat# ab756, mouse anti-human, Abcam; 1:50). 
IHC was performed using the double stain kit (Dako) according 
to the manufacturer’s instructions. For immunofluorescence, 
specimens were incubated with Alexa Fluor secondary antibodies 
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(Thermo Fisher, China). For negative control, isotype-matched 
antibodies were used. Immunostaining was evaluated using TMAJ 
Image (http://tmaj.pathology.jhmi.edu) computerized image anal-
ysis. The accuracy of automated measurements was confirmed by 
independent evaluation by two pathologists (YZ and NO). Cells 
stained with the indicated antibodies were counted at 400× magni-
fication in at least 10 fields per section. 
Co-culture of naive CD4+ T cells and DCs
2 × 103-1 × 104 TI DCs and PB DCs, and autologous PB CD4+ 
naive T cells were isolated as described above and co-cultured 
(1:10-20 DCs:T cells) [19] in growth medium (RPMI 1640 with 
10% FBS and 25 U/ml IL-2) with or without 30% CM from au-
tologous tumor slices or adjacent normal tissue slices for 9 days. 
Non-adherent T cells were then harvested for further experiments.
Suppression assay
DC-primed Tregs were harvested, purified using CD25 (130-
092-983, Miltenyi) and CD127 (130-094-945, Miltenyi) microbe-
ads, and evaluated for their suppressive capacity as previously 
described [46, 47]. Briefly, immature myeloid DCs were produced 
by culturing autologous monocytes isolated from PB in DMEM 
containing 25 ng/ml GM-CSF, 5 ng/ml IL-4 (PeproTech) and 10% 
heat-inactivated autologous serum for 6 days. The cultures were 
replaced with fresh medium and cytokines every 3 days, and cell 
differentiation was monitored by light microscopy. Myeloid DCs 
were matured by incubation with 100 ng/ml LPS and 500 U/ml 
IFN-γ (PeproTech) for 48 h and then pulsed for 24 h with lysates 
(200 µg protein/1 × 106 cells/ml) from isolated autologous tumor 
cells lysed by 5 freeze/thaw cycles. Autologous CD8+ T cells iso-
lated from PB were labeled with 0.5 µM CFSE (Invitrogen) for 
15 min at RT and incubated with mature myeloid DCs (5:1) in the 
presence or absence of DC-primed Tregs at the indicated ratios in 
RPMI 1640 medium supplemented with 5 µg/ml IL-12, 25 mmol/l 
HEPES, 4 mmol/l l-glutamine, 25 µmol/l 2-mercaptoethanol and 
10% heat-inactivated autologous serum. Proliferation of CD8+ T 
cells was measured by CFSE staining and flow cytometry after 5 
days.
Cytotoxicity assay
The Live/Dead Cell Mediated Cytotoxicity Kit (Molecular 
Probes) was used as previously described [48]. Briefly, primary 
breast cancer cells were stained with 3,39-dioctadecyloxacar-
bocyanine (DiOC18) for 15 min at RT. Tumor-specific CD8+ T 
cells (2 × 104), generated by incubation with tumor lysate-pulsed 
DCs as described above, were harvested using CD8 microbeads 
(130-045-201, Miltenyi) and added to cancer cells stained with 
propidium iodide (3.75 mM solution, 1:500 final dilution) at an ef-
fector-to-target ratio of 10:1. After 18 h, cells were harvested and 
analyzed by flow cytometry.
Ex vivo tumor slice migration assay
Ex vivo tumor slice migration assay was performed as previous-
ly described [23]. Briefly, freshly resected samples were embedded 
in 5% agarose (type VII-A; Sigma-Aldrich), 400 µm slices were 
cut with a vibratome (VT 1000S; Leica), overlaid with 2 × 105 
autologous naive CD4+ T cells isolated from PB and labeled with 
CFSE, and incubated in 24-well plates containing RPMI 1640 plus 
10% autologous serum for 3 h. The slices were then rinsed, fixed 
and stained with anti-CCL18 (Cat# MAB394, R&D). Cells were 
counted in at least 10 fields of view per section at 400× magnifica-
tion.
In vivo migration assay
In vivo migration was assayed as previously described [30] 
with slight modifications. Healthy donor PB naive CD4+ T cells 
(1 × 106) were labeled with CFSE and injected via tail vein into 
female NOD/scid mice, bearing tumors formed 14 days earlier 
by mammary fat pad injection of 2 × 106 MDA-MB-231 cells 
(American Type Culture Collection), with or without 2 × 106 
autologous macrophages. For inhibition experiments, 10 µg per 
mouse of isotype control (Cat# ab172569, Abcam) or anti-CCL18 
(Cat# ab9849, Abcam) was added to naive CD4+ T cells before in-
jection. For recombinant protein treatment, rhCCL18 (0.1 mg/kg, 
PeproTech, Rocky Hill, NJ, USA) was injected intratumorally into 
MDA-MB-231 xenografts 1 h before T cells were injected. Xe-
nografts were harvested 24 h after T cell injection and sectioned. 
CFSE+ cells were counted in at least 10 fields per section at 400× 
magnification.
Flow cytometry
Cells were stained with CD3 FITC (Cat# 11-0039), CD3 eFluor 
450 (Cat# 48-0038), CD4 PE-Cyanine7 (Cat# 25-0049), CD4 Per-
CP-Cyanine5.5 (Cat# 560650, BD Pharmingen), Foxp3 APC (Cat# 
17-4777), Foxp3 PE (Cat# 12-4776), CD45RA PE (Cat# 130-
092-248, Miltenyi), CD45RA APC (Cat# 130-092-249, Miltenyi), 
CD62L APC (Cat# 17-0629), CD25 PE (Cat# 130-091-024, 
Miltenyi), CD25 APC-H7 (Cat# 560225, BD Pharmingen), CD8 
PE-Cyanine7 (Cat# 25-0088), Perforin PE (Cat# 12-9994), gran-
zyme B PE (Cat# 12-8899), CCR8 APC (Cat# FAB1429A, R&D 
System), CD4 FITC (Cat# 11-0049), CD45 APC (Cat# 17-9459), 
CD14 PE (Cat# 12-0149), CD45RO PE (Cat# 12-0457), CD45RO 
eFluor 450 (Cat# 48-0457), CD127 APC (Cat# 17-1278). PIT-
PNM3 antibody (Cat# NBP1-31070, Novus) was labeled with 
APC by Abcam APC Conjugation Kit (ab201807, Abcam) accord-
ing to the manufacturer’s instructions. For the intracellular stain, 
cells were pretreated with Intracellular Fixation and Permeabili-
zation kit (Cat# 88-8824) according to the manufacturer’s instruc-
tions. All the reagents were from eBioscience unless indicated 
otherwise. Cells were subsequently analyzed by multicolor flow 
cytometry (Gallios, Beckman Coulter, China).
qRT-PCR
qRT-PCR was performed with a LightCycler 480 instrument 
(Roche Diagnostics, Switzerland), using the SYBR Premix Ex Taq 
TM (TaKaRa, Japan) according to the manufacturer’s instruction. 
For absolute quantitative PCR, we determine the absolute level 
of PITPNM3 mRNAs as previously reported [49]. Briefly, we 
constructed standard sample using the same primers of PITPNM3 
as for real-time PCR, the amplified DNA fragments were purified 
and cloned into pEASY-T5 Zero cloning vector (CT501, Trans-
Gen Biotech, China), and transformed into DH5α competent cells 
(TaKaRa). Finally, plasmid DNA was extracted using Plasmid 
Mini Kit (D6943, Omega Bio-Tek, Doraville, USA). Equivalent 
molecules per cell were extrapolated from the standard curve and 
threshold cycle (Ct) values, based on the assumption that total 
RNA per cell is 20 pg. The primer sequences are listed in Supple-
mentary information, Table S6.
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Muc1-specific CTL assay
A Muc1 peptide (LLLLTVLTV) and a HER-2-/neu-derived 
peptide (KIFGSLAFL) were synthesized by Abgent Biotech Ltd 
(Suzhou, China) [50]. DCs from HLA-A2+ patients (determined 
by flow cytometry analysis for HLA-A2, Cat# 343303, Bioleg-
end) with tumors expressing Muc1 (determined by IHC staining 
for Muc1, Cat# ab109185, Abcam) were pulsed with 50 µg/ml 
synthetic peptide for 8 h, washed, and incubated with autologous 
CD8+ T cells (1:5) isolated from PB in the presence or absence of 
DC-primed Tregs at various ratios in RPMI 1640 medium supple-
mented with 5 µg/ml IL-12, 25 mmol/l HEPES, 4 mmol/l l-glu-
tamine, 25 µmol/l 2-mercaptoethanol and 10% heat-inactivated 
autologous serum. Antigen specificity of tumor cell lysis was fur-
ther determined in a cold target inhibition assay by analyzing the 
capacity of unlabeled T2 cells (American Type Culture Collection) 
coated with the Muc1 peptide or the HER-2/neu-derived peptide 
to block lysis of tumor cells at a ratio of 20:1 (inhibitor to target 
ratio).
Primary T cell transduction
Primary T cell transduction was performed as described before 
[51]. Briefly, primary T cells were isolated from PB of healthy 
donors as described above and cultured in growth medium (RPMI 
1640 with 10% fetal bovine serum and 25 U/ml IL-2). After 12 h, 
PITPNM3 shRNAs with previously proved potency and specific-
ity were delivered [24] to T cells by 2-4 × 107 lentiviral particles 
(multiplicity of infection (MOI) of 10-20, Genepharma, Shanghai, 
China) supplemented with 8 µg/ml Polybrene (Sigma) for 8-10 h, 
then the cell suspension was spun and replaced with the growth 
medium. The transduction was repeated in two consecutive days 
and T cells were collected for later experiments.
Cell immunofluorescent staining
Naive CD4+ T cells isolated from PB of healthy donors were 
incubated with primary antibodies against CCL18 (Cat# MAB394, 
mouse anti-human, R&D; 20 µg/ml) or PITPNM3 (Cat# NBP1-
31070, rabbit anti-human, Novus; 1:100), followed by incubation 
with Alexa Fluor 488 donkey anti-mouse IgG (H+L) and Alexa 
Fluor 555 goat anti-rabbit IgG (H+L) (Thermo Fisher). For confo-
cal microscopy, the cells on cover slips were counterstained with 
DAPI and imaged using a confocal laser-scanning microscope (Carl 
Zeiss) with a core data acquisition system (Applied Precision). 
Binding assays
Competition experiments were performed by using 125I-labeled 
CCL18 and the indicated concentrations of unlabeled chemokines 
as previously described [21]. Briefly, 2 nM 125I-labeled CCL18 
was incubated with 2 × 105 naive CD4+ T cells isolated from PB 
of healthy donors resuspended in 100 µl binding buffer (50 nM 
HEPES, pH 7.2, 1 mM CaCl2, 5 mM MgCl2, 0.5% BSA) in the 
presence of the indicated concentrations of unlabeled CCL18. 
After incubation at room temperature (RT) for 1 h, the cells were 
pelleted through a PBS cushion with 10% sucrose for 1 min at 
10 000× g. The supernatant was removed and the radioactivity 
associated with cell pellets was measured using a liquid scintil-
lation counter (CliniGamma, Pharmacia). Each data point was 
determined in triplicate. Binding data were analyzed with Prism 
computer program by GraphPad (San Diego, CA, USA).
Western blot
Protein extracts were resolved through 8%-15% SDS-PAGE, 
transferred to PVDF membranes, and probed with antibodies 
against PITPNM3 (Cat# NBP1-31070, Novus), Akt (Cat# 4685, 
CST), phospho-Akt (Cat# 4060, CST), ERK (Cat# 4695, CST), 
phospho-ERK (Cat# 4370, CST), GAPDH (Cat# HRP-60004, Pro-
teintech). Peroxidase-conjugated anti-mouse or -rabbit antibody 
(CST) was used as secondary antibody and the antigen-antibody 
reaction was visualized by enhanced chemiluminescence assay 
(ECL, Thermo).
Calcium mobilization assay
Naive CD4+ T cells isolated from PB of healthy donors were 
suspended at 3 × 106 cells/ml in Hank’s balanced salt solution 
(HBSS) containing 1 mg/ml of bovine serum albumin (BSA) and 
10 mM HEPES, pH 7.4 (HBSS-BSA) and incubated with 1 mM 
Fura-2-AM (Dojindo, Kumamoto, Japan) at RT for 30 min in the 
dark. After washing twice with HBSS-BSA, cells were suspended 
in HBSS-BSA at 2.5 × 106 cells/ml. 2 ml of the cell suspension in 
a quartz cuvette was placed in a luminescence spectrometer (RF-
5000, Shimadzu, Kyoto, Japan) and fluorescence was monitored at 
an emission wavelength of 510 nm, and excitation wavelengths of 
340 and 380 nm every 20 ms. Calibration of fluorescence in terms 
of [Ca2+]i was calculated from the ratio 340/380 excitation fluores-
cent values. 
Chemotaxis assays
For chemotaxis assays, the indicated T cells isolated from PB 
of healthy donors transmigrated across 5-mm transwell filters 
(Costar, Cambridge, MA, USA) for 6 h to medium with or without 
20 ng/ml rhCCL18 (PeproTech) in the bottom chamber, and were 
enumerated by flow cytometry [52]. Transwell assays were per-
formed in triplicate and repeated using cells from a minimum of 
three different donors.
Humanized mouse experiments
Animal work was approved by the Institutional Review Boards 
and Animal Care and Use Committees of Sun Yat-Sen University 
and the University of Hong Kong. Humanized mice were generat-
ed from NOD/SCID/IL2rγnull (NSG) mice (Jackson Laboratories) 
as previously described [27, 53]. Fresh human CB and fetal thymi 
were obtained from Sun Yat-Sen Memorial Hospital, according 
to guidelines approved by the hospital Ethics Boards and Clinical 
Research Committee. CD34+ HSCs were isolated to > 95% purity 
using two rounds of selection with the direct CD34 Progenitor Cell 
Isolation Kit (Miltenyi Biotec) from CB mononuclear cells isolat-
ed by Ficoll-Hypaque density gradient centrifugation. Briefly, 3-4-
week female NSG mice bearing human surgical thymic grafts were 
subjected to 200 cGy total body irradiation 12 h before tail vein 
injection with 2 × 105 HSCs in 0.2 ml of medium [54]. Mice were 
injected with 0.1 ml of human M-CSF-encoding lentiviral vectors 
(5-10 × 108 total TU/ml) via tail vein 1 week after transplantation 
[24]. Six weeks after HSC transplantation, 2 × 106 MDA-MB-231 
cells, stably expressing luciferase, were injected into the mammary 
fat pad. For AsiC treatment, mice were injected intraperitoneally 
with PBS, CD4-AsiC-con (1 nmol) or CD4-AsiC-PI (1 nmol) 
daily for 14 days [55] after xenografts were palpable using AsiCs 
from TriLink BioTechnologies. Tumor growth was evaluated by 
monitoring tumor volume (TV = length × width2 × 0.5) every 5 
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days. Whole-body tumor burden of animals bearing xenografts 
was assessed after luciferin injection using the IVIS Lumina Imag-
ing System (Xenogen). Animals were sacrificed when xenografts 
reached 1.5 cm in diameter. The blood, tumor xenografts and lungs 
of the sacrificed mice were harvested for further investigation. 
Total RNA was extracted from lungs for qRT-PCR analysis of hu-
man HPRT mRNA expression. For some experiments, autologous 
CD4+CD25+CD127− Tregs were also isolated from CB by magnet-
ic bead isolation (Miltenyi Biotec) and cryopreserved. Four weeks 
after HSC transplantation, Tregs were thawed and expanded ex 
vivo with 1 000 U/ml of rhIL-2, 5 ng/ml rhTGF-β (PeproTech) and 
αCD3/αCD28 beads (Invitrogen) in a 1:2 cell to bead ratio for two 
7-day rounds of stimulation. The expanded Tregs (1 × 105) were 
labeled with CFSE for 15 min at RT and intravenously injected 
into humanized mice every 10 days as indicated.
Statistics
All statistical analyses were performed using SPSS for Win-
dows version 13.0 (SPSS, Chicago, IL, USA). Pearson correlation 
and regression analysis was used to assess the relationship be-
tween naive CD4+ T cell number, Treg cell number and CCL18+ 
cell number in human breast tissue. X-Tile statistical software was 
used to group clinical samples. Kaplan-Meier survival curves were 
plotted and log-rank test was done. All in vitro experiments were 
performed in triplicate in least three independent experiments. P < 
0.05 was considered statistically significant.
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